Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer

Anticancer Research

Volumn 26, Issue 2 B, 2006, Pages 1583-1587

  Miyake, Hideaki ^a   Muramaki, Mototsugu ^b   Kurahashi, Toshifumi ^b   Yamanaka, Kazuki ^b   Hara, Isao ^b   Fujisawa, Masato ^a  

^a HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Heat shock protein 27; Neoadjuvant hormonal therapy; Prostate cancer; Radical prostatectomy

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; HEAT SHOCK PROTEIN 27; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; GLEASON SCORE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TREATMENT OUTCOME; UPREGULATION;

AGED; ANILIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLUTAMIDE; GOSERELIN; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LEUPROLIDE; MALE; NEOADJUVANT THERAPY; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 33645824981     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Morimoto RI: Cells in stress: transcriptional activation of heat shock genes. Science 259: 1409-1410, 1993.
2. Lebret T, Watson RW and Fitzpatrick JM: Heat shock proteins: their role in urological tumors. J Urol 169: 338-346, 2003.
3. Gabai VL, Budagova KR and Sherman MY: Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. Oncogene 24: 3328-3338, 2005.
4. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y and Foster CS: Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 60: 7099-7105, 2000.
5. Gibbons NB, Watson RW, Coffey RN, Brady HP and Fitzpatrick JM: Heat-shock proteins inhibit induction of prostate cancer cell apoptosis. Prostate 45: 58-65, 2000.
6. Thomas SA, Brown IL, Hollins GW, Hocken A, Kirk D, King RJ and Leake RE: Detection and distribution of heat shock proteins 27 and 90 in human benign and malignant prostatic tissue. Br J Urol 77: 367-372, 1996.
7. Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamaki E, Schraml P, Moch H, Willi N, Elkahloun AG, Pretlow TG, Gasser TC, Mihatsch MJ, Sauter G and Kallioniemi OP: Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 91: 1758-1764, 1999.
8. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K and Gleave M: Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64: 6595-6602, 2004.
9. Solit DB, Scher HI and Rosen N: Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 30: 709-716, 2003.
10. Gao C, Zou Z, Xu L, Moul J, Seth P and Srivastava S: p53-dependent induction of heat shock protein 27 (HSP27) expression. Int J Cancer 88: 191-194, 2000.
11. Madersbacher S, Grobl M, Kramer G, Dirnhofer S, Steiner GE and Marberger M: Regulation of heat shock protein 27 expression of prostatic cells in response to heat treatment. Prostate 37: 174-1781, 1998.
12. Roigas J, Wallen ES, Loening SA and Moseley PL: Estramustine phosphate enhances the effects of hyperthermia and induces the small heat shock protein HSP27 in the human prostate carcinoma cell line PC-3. Urol Res 30: 130-135, 2002.
13. International Union Against Cancer: TNM Classification of Malignant Tumors, Sobin LH and Wittekind CH (eds.). New York, John Wiley & Sons, pp. 170-173, 1997.
14. Kurahashi T, Muramaki M, Yamanaka K, Hara I and Miyake H: Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. BJU Int 96: 895-899, 2005.
15. Rosenberg J and Small EJ: Prostate cancer update. Curr Opin Oncol 15: 217-221, 2003.
16. So A, Gleave M, Hurtado-Col A and Nelson C: Mechanisms of the development of androgen independence in prostate cancer. World J Urol 23: 1-9, 2005.